-The Times of India Almost one in three drugs (36%) found "not of standard quality" from across India last year were from Maharashtra (23%) and Tamil Nadu (13%) alone. Around 9.2% of the rest of the sub-standard quality drugs were from Kerala, Gujarat (8.5%), Karnataka (7.2%), Uttar Pradesh (6.9%), Jammu & Kashmir (6.08%) and Rajasthan (5.8%). Union health minister Ghulam Nabi Azad said on Tuesday that of the 48, 082 drug samples tested...

-The Indian Express At a time when the government is struggling to get past objections from its coalition partners to attract investment in certain sectors such as retail, aviation and pensions fund management, a grim internecine ministerial battle has applied the brakes on foreign direct investment flow into one of the more attractive and lucrative sectors — pharmaceuticals. Clearances for over Rs 1,000 crore FDI in this sector, the second largest in...

-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...

Tuberculosis re-emerges as a major threat as new drug-resistant strains develop because of mismanagement of the disease. At the beginning of the year, doctors at Mumbai’s P.D. Hinduja National Hospital and Medical Research Centre reported that they had 12 patients infected with TDR-TB, or totally drug-resistant tuberculosis, a condition in which the TB bacilli is resistant to all first- and second-line drugs used in the conventional treatment of the disease. Panic...

-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...